The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants

Corvaglia, Luigi; Aceti, Arianna; Mariani, Elisa; Giorgi, M. De; Capretti, Maria Grazia; Faldella, Giacomo

doi:10.1111/j.1365-2036.2010.04545.x

Cited by 38 publications

(35 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In that study, as well as our own, 3 sodium alginate appears to be an effective treatment option for GERD. However, due to the small number of patients included and the short duration of therapy, these studies are not able to evaluate the drug’s safety.…”

mentioning

confidence: 55%

Efficacy and safety of sodium alginate for GERD in preterm infants: authors’ reply

Corvaglia

Aceti

Faldella

2011

Alimentary Pharmacology &Amp; Therapeutics

Self Cite

View full text Add to dashboard Cite

In conclusion, although both studies focused on a short-term, hospital-based intervention for high-risk preterm infants, sodium alginate treatment for reflux seems to be safe and effective.We think that the results and conclusions of these small-size studies should serve to stimulate larger investigations to clarify their preliminary findings. Further work is needed in this field to identify optimal treatment regimes as, until this is achieved, clinicians will continue to work with limited choices.

show abstract

mentioning

confidence: 55%

Efficacy and safety of sodium alginate for GERD in preterm infants: authors’ reply

Corvaglia

Aceti

Faldella

2011

Alimentary Pharmacology &Amp; Therapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similarly, Corvaglia et al . conducted a clinical trial study to determine the effect of sodium alginate in preterm newborns suffering from GOR using pH and impedance monitoring techniques and observed a reduction in the number of acid reflux episodes . In a second clinical trial, Corvaglia et al .…”

Section: Resultsmentioning

confidence: 99%

Raft‐forming polysaccharides for the treatment of gastroesophageal reflux disease (GORD): Systematic review

Yousaf

Nirwan

Smith

et al. 2019

J of Applied Polymer Sci

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GORD) is a common condition induced by unwarranted reflux of gastric and duodenal contents into the esophagus, and insufficient clearance of refluxate from it. Pharmaceutical formulations possessing raft‐forming capability offers an excellent alternative to conventional treatment options to treat uncomplicated GORD. These formulations typically contain a polymer, which performs distinctively upon contact with gastric acid and develops a foam‐like structure that can float on gastric contents. This review aims to feature research articles and patents that cover this topic. After undergoing a standardized literature search following preferred reporting items for systematic reviews and meta‐analyses guidelines, we have included 38 research articles and 18 patents describing the role of raft‐forming polymers in the treatment of GORD. This is a comprehensive review of formulation/testing of raft‐forming polymers. As expected, the majority of the studies focused on alginate; however, fewer studies have reported the use of pectin, xanthan gum, and raw psyllium fibers (husk). Moreover, it can be concluded from this comprehensive systematic review that a detailed characterization of raft‐forming formulations, type, and concentration of used active and inactive materials and different formulations factors are essential for the development of successful anti‐reflux raft‐forming formulations. © 2019 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2019, 136, 48012.

show abstract

“…In a previous study [63] we have evaluated the effectiveness of a formulation containing sodium alginate and sodium bicarbonate (Gaviscon Reckitt Benckiser Healthcare), administered 4 times a day at a dosage of 0.25 mL/kg, to improve many GER's features in preterm infants. Sodium alginate decreased the number of acid GER episodes and total acid esophageal exposure, detected by pH-monitoring.…”

Section: Pharmacological Therapymentioning

confidence: 99%

Pharmacological Therapy of Gastroesophageal Reflux in Preterm Infants

Corvaglia

Monari

Martini

et al. 2013

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Although gastroesophageal reflux (GER) is a very common phenomenon among preterm infants, its therapeutic management is still an issue of debate among neonatologists. A step-wise approach should be advisable, firstly promoting nonpharmacological interventions and limiting drugs to selected infants unresponsive to the conservative measures or who are suffering from severe GER with clinical complications. Despite of this, a concerning pharmacological overtreatment has been increasingly reported. Most of the antireflux drugs, however, have not been specifically assessed in preterm infants; moreover, serious adverse effects have been noticed in association to their administration. This review mainly aims to draw the state of the art regarding the pharmacological management of GER in preterm infants, analyzing the best piecies of evidence currently available on the most prescribed anti-reflux drugs. Although further trials are required, sodium alginate-based formulations might be considered promising; however, data regarding their safety are still limited. Few piecies of evidence on the efficacy of histamine-2 receptor blockers and proton pump inhibitors in preterm infants with GER are currently available. Nevertheless, a significantly increased risk of necrotizing enterocolitis and infections has been largely reported in association with their use, thereby leading to an unfavorable risk-benefit ratio. The efficacy of metoclopramide in GER's improvement still needs to be clarified. Other prokinetic agents, such as domperidone and erythromycin, have been reported to be ineffective, whereas cisapride has been withdrawn due to its remarkable cardiac adverse effects.

show abstract

The efficacy of sodium alginate (Gaviscon) for the treatment of gastro-oesophageal reflux in preterm infants

Abstract: SUMMARY BackgroundGastro-oesophageal reflux is common in preterm newborns; at present, no studies have evaluated the efficacy of sodium alginate in this population.

Cited by 38 publications

References 20 publications

Efficacy and safety of sodium alginate for GERD in preterm infants: authors’ reply

Efficacy and safety of sodium alginate for GERD in preterm infants: authors’ reply

Raft‐forming polysaccharides for the treatment of gastroesophageal reflux disease (GORD): Systematic review

Pharmacological Therapy of Gastroesophageal Reflux in Preterm Infants

Contact Info

Product

Resources

About